FDA Approved Roche’s Perjeta For Breast Cancer

Aug. 7 | Roche Holding AG confirmed that the U.S. Food and Drug Administration (FDA) approved Perjeta (pertuzumab) in combination with Herceptin and docetaxel chemotherapy for the treatment of people with HER2-positive metastatic breast cancer who have not received...

Drug Combos May Fight Advanced Breast Cancers

Dec. 15 | The researchers on breast cancer are reportedly encouraged by the results of two new studies that show combination therapies might improve survival for women with two different types of advanced tumors. One of the drugs, everolimus (Afinitor), boosted...